Swiss ophthalmology biotech Oculis has suffered a major setback for its most advanced ophthalmology programme after two pivotal Phase III trials of OCS-01 eye drops in diabetic macular edema failed to meet their primary endpoint.
French pharmaceutical group Servier has agreed to acquire sevasemten and the muscular dystrophy business built around it from US biotech Edgewise Therapeutics Inc. in a transaction worth up to US$2.65bn, giving the Paris-based company a late-stage entry into Becker and Duchenne muscular dystrophy.
ROGER HARRIS/SCIENCE PHOTO LIBRA-stock.adobe.comT-CURX acquires Pantherna: does this mark the start of a new race for the next generation of CAR-T therapies? The Würzburg- and Munich-based CAR-T company T-CURX is acquiring the Berlin-based mRNA and LNP company Pantherna Therapeutics. Financial details of the transaction were not disclosed. Pantherna is to continue operating in Hennigsdorf as a wholly owned subsidiary.
French immunotherapy developer OSE Immunotherapeutics has signed a term sheet for a flexible bridge equity financing with IRIS Capital Investment, giving the Nantes- and Paris-based biotech access to up to €19.3m in gross proceeds over 24 months.
Nuclidium AGBasel-based Nuclidium AG has secured an additional tranche for its ongoing Series B financing round, bringing the total to approximately €115 million. The theranostics company is developing copper-based radiopharmaceuticals that are used both for diagnostic imaging and therapeutic applications.
GSK has linked its chronic hepatitis B drug candidate to a 19% functional cure rate across a pair of Phase III trials, clearing the bar it set for clinical relevance.
Swedish rare immunology specialist Hansa Biopharma AB has reported positive topline results from a European post-authorisation efficacy study of Idefirix, strengthening its case to convert the kidney transplant drug’s conditional EU approval into full marketing authorisation.
Perceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL.
Adcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor.
CDC/Janice Haney CarrShopping spree at Eli Lilly? The US pharma giant is acquiring no fewer than three companies, all active in infectious diseases. Among them is Swiss biotech LimmaTech Biologics AG, led by former CureVac CEO Franz-Werner Haas. Yet Lilly’s ambitions extend well beyond classical infectious disease markets, targeting areas ranging from autoimmune disorders and antimicrobial resistance to chronic immune dysfunction and even cancer.